Is WHWK or BOLD more profitable?

Boundless Bio's return on equity of -53.60% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -79.63% -74.01% Boundless Bio N/A -53.60% -34.66%

Do analysts prefer CNTN or BOLD?

Boundless Bio has a consensus price target of $4.00, indicating a potential upside of 55.64%. Given Boundless Bio's stronger consensus rating and higher probable upside, analysts clearly believe Boundless Bio is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher valuation & earnings, CNTN or BOLD?

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A Boundless Bio N/A N/A -$58.20M -$2.50 N/A

Is CNTN or BOLD more profitable?

Hillstream Biopharma's return on equity of -31.50% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% Boundless Bio N/A -53.60% -34.66%

Do analysts recommend BOLD or MENS?

Boundless Bio currently has a consensus target price of $4.00, suggesting a potential upside of 55.64%. Given Boundless Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Boundless Bio is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, BOLD or MENS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boundless Bio N/A N/A -$58.20M -$2.50 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is BOLD or MENS more profitable?

Jyong Biotech's return on equity of 0.00% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -53.60% -34.66% Jyong Biotech N/A N/A N/A

Which has higher valuation and earnings, BOLD or ANTX?

Anthem is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boundless Bio N/A N/A -$58.20M -$2.50 N/A Anthem N/A N/A -$35.17M -$1.10 N/A

Is BOLD or ANTX more profitable?

Anthem's return on equity of -52.35% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -53.60% -34.66% Anthem N/A -52.35% -47.25%

Is SPRB or BOLD more profitable?

Boundless Bio's return on equity of -53.60% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -155.40% -101.67% Boundless Bio N/A -53.60% -34.66%

Boundless Bio (BOLD) Competitors

$2.57 +0.05 (+1.98%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.56 0.00 (-0.19%)

As of 07/24/2026 07:34 PM Eastern

Compare

BOLD vs. WHWK, CNTN, MENS, ANTX, and SPRB

Should you buy Boundless Bio stock or one of its competitors? MarketBeat compares Boundless Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Boundless Bio include Whitehawk Therapeutics (WHWK), Hillstream Biopharma (CNTN), Jyong Biotech (MENS), Anthem (ANTX), and Spruce Biosciences (SPRB).

How does Boundless Bio compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Boundless Bio (NASDAQ:BOLD) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 23.1% of Boundless Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Whitehawk Therapeutics presently has a consensus target price of $8.20, indicating a potential upside of 121.02%. Boundless Bio has a consensus target price of $4.00, indicating a potential upside of 55.64%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Whitehawk Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Whitehawk Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than Boundless Bio. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 1 mentions for Boundless Bio. Whitehawk Therapeutics' average media sentiment score of 1.89 beat Boundless Bio's score of 1.87 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Whitehawk Therapeutics	Very Positive
Boundless Bio	Very Positive

Whitehawk Therapeutics has higher revenue and earnings than Boundless Bio. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	25.69	-$20.60M	-$1.68	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A

Boundless Bio's return on equity of -53.60% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
Boundless Bio	N/A	-53.60%	-34.66%

Summary

Whitehawk Therapeutics beats Boundless Bio on 11 of the 14 factors compared between the two stocks.

How does Boundless Bio compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and Boundless Bio (NASDAQ:BOLD) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Boundless Bio has a consensus price target of $4.00, indicating a potential upside of 55.64%. Given Boundless Bio's stronger consensus rating and higher probable upside, analysts clearly believe Boundless Bio is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A

In the previous week, Hillstream Biopharma had 1 more articles in the media than Boundless Bio. MarketBeat recorded 2 mentions for Hillstream Biopharma and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.87 beat Hillstream Biopharma's score of 0.62 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Hillstream Biopharma	Positive
Boundless Bio	Very Positive

Hillstream Biopharma has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

Hillstream Biopharma's return on equity of -31.50% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Boundless Bio	N/A	-53.60%	-34.66%

1.2% of Hillstream Biopharma shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 23.1% of Boundless Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Hillstream Biopharma beats Boundless Bio on 7 of the 13 factors compared between the two stocks.

How does Boundless Bio compare to Jyong Biotech?

Boundless Bio (NASDAQ:BOLD) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

In the previous week, Jyong Biotech had 1 more articles in the media than Boundless Bio. MarketBeat recorded 2 mentions for Jyong Biotech and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.87 beat Jyong Biotech's score of 1.25 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Boundless Bio	Very Positive
Jyong Biotech	Positive

Boundless Bio currently has a consensus target price of $4.00, suggesting a potential upside of 55.64%. Given Boundless Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Boundless Bio is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Jyong Biotech's return on equity of 0.00% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-53.60%	-34.66%
Jyong Biotech	N/A	N/A	N/A

Summary

Boundless Bio and Jyong Biotech tied by winning 4 of the 8 factors compared between the two stocks.

How does Boundless Bio compare to Anthem?

Boundless Bio (NASDAQ:BOLD) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Anthem's return on equity of -52.35% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-53.60%	-34.66%
Anthem	N/A	-52.35%	-47.25%

Anthem is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A

Boundless Bio presently has a consensus price target of $4.00, indicating a potential upside of 55.64%. Anthem has a consensus price target of $9.00, indicating a potential upside of 82.93%. Given Anthem's stronger consensus rating and higher possible upside, analysts clearly believe Anthem is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Anthem had 5 more articles in the media than Boundless Bio. MarketBeat recorded 6 mentions for Anthem and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.87 beat Anthem's score of 0.57 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Boundless Bio	Very Positive
Anthem	Positive

Boundless Bio has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market. Comparatively, Anthem has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market.

90.5% of Anthem shares are held by institutional investors. 23.1% of Boundless Bio shares are held by company insiders. Comparatively, 22.6% of Anthem shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Anthem beats Boundless Bio on 8 of the 13 factors compared between the two stocks.

How does Boundless Bio compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Boundless Bio (NASDAQ:BOLD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Spruce Biosciences has higher revenue and earnings than Boundless Bio. Spruce Biosciences is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	24.13	-$38.97M	-$36.60	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A

In the previous week, Spruce Biosciences and Spruce Biosciences both had 1 articles in the media. Spruce Biosciences' average media sentiment score of 1.89 beat Boundless Bio's score of 1.87 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Spruce Biosciences	Very Positive
Boundless Bio	Very Positive

Spruce Biosciences presently has a consensus price target of $162.63, suggesting a potential upside of 277.50%. Boundless Bio has a consensus price target of $4.00, suggesting a potential upside of 55.64%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Spruce Biosciences is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

91.7% of Spruce Biosciences shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 23.1% of Boundless Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Boundless Bio's return on equity of -53.60% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Boundless Bio	N/A	-53.60%	-34.66%

Spruce Biosciences has a beta of 3.16, suggesting that its stock price is 216% more volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

Summary

Spruce Biosciences beats Boundless Bio on 8 of the 13 factors compared between the two stocks.

Get Boundless Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLD vs. The Competition

Export

Metric	Boundless Bio	PHARMACEUTICAL PREPARATIONS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$56.61M	$966.52M	$6.88B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	-1.03	1.53	27.00	23.71
Price / Sales	N/A	109.17	492.22	75.59
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	0.58	8.48	10.28	6.07
Net Income	-$58.20M	-$3.23M	$3.60B	$331.84M
7 Day Performance	3.63%	-2.80%	-1.25%	-1.53%
1 Month Performance	2.39%	-4.40%	-0.35%	-2.46%
1 Year Performance	103.97%	28.83%	18.41%	13.66%

Boundless Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLD Boundless Bio	3.5792 of 5 stars	$2.57 +2.0%	$4.00 +55.6%	+106.4%	$56.61M	N/A	N/A	64	Positive News
WHWK Whitehawk Therapeutics	2.4559 of 5 stars	$3.89 +1.0%	$8.20 +110.8%	+91.2%	$192.37M	N/A	N/A	21	News Coverage
CNTN Hillstream Biopharma	0.2423 of 5 stars	$2.34 -2.1%	N/A	N/A	$184.32M	N/A	N/A	2	News Coverage
MENS Jyong Biotech	N/A	$2.30 +0.4%	N/A	-80.0%	$174.87M	N/A	N/A	31	News Coverage Positive News Gap Down
ANTX Anthem	2.3285 of 5 stars	$4.67 flat	$9.00 +92.7%	+345.2%	$168.20M	N/A	N/A	N/A	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLD) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boundless Bio (BOLD) Competitors

BOLD vs. WHWK, CNTN, MENS, ANTX, and SPRB

How does Boundless Bio compare to Whitehawk Therapeutics?

Summary

How does Boundless Bio compare to Hillstream Biopharma?

Summary

How does Boundless Bio compare to Jyong Biotech?

Summary

How does Boundless Bio compare to Anthem?

Summary

How does Boundless Bio compare to Spruce Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boundless Bio (BOLD) Competitors

BOLD vs. WHWK, CNTN, MENS, ANTX, and SPRB

How does Boundless Bio compare to Whitehawk Therapeutics?

Do insiders and institutionals believe in WHWK or BOLD?

Do analysts recommend WHWK or BOLD?

Which has more risk and volatility, WHWK or BOLD?

Does the media prefer WHWK or BOLD?

Which has higher valuation & earnings, WHWK or BOLD?

Is WHWK or BOLD more profitable?

Summary

How does Boundless Bio compare to Hillstream Biopharma?

Do analysts prefer CNTN or BOLD?

Which has higher valuation & earnings, CNTN or BOLD?

Does the media prefer CNTN or BOLD?

Which has more risk and volatility, CNTN or BOLD?

Is CNTN or BOLD more profitable?

Do institutionals & insiders hold more shares of CNTN or BOLD?

Summary

How does Boundless Bio compare to Jyong Biotech?

Does the media prefer BOLD or MENS?

Do analysts recommend BOLD or MENS?

Which has higher earnings and valuation, BOLD or MENS?

Is BOLD or MENS more profitable?

Summary

How does Boundless Bio compare to Anthem?

Is BOLD or ANTX more profitable?

Which has higher valuation and earnings, BOLD or ANTX?

Do analysts recommend BOLD or ANTX?

Does the media favor BOLD or ANTX?

Which has more risk and volatility, BOLD or ANTX?

Do institutionals and insiders hold more shares of BOLD or ANTX?

Summary

How does Boundless Bio compare to Spruce Biosciences?

Which has preferable valuation & earnings, SPRB or BOLD?

Does the media favor SPRB or BOLD?

Do analysts prefer SPRB or BOLD?

Do institutionals and insiders hold more shares of SPRB or BOLD?

Is SPRB or BOLD more profitable?

Which has more volatility & risk, SPRB or BOLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools